2020年10月至2021年9月英格兰新冠疫苗接种后首剂与第二剂不良事件:国家疫苗监测平台自对照病例系列研究
该研究利用英格兰国家哨点网络数据,采用自对照病例系列设计,在7,952,861条记录中分析781,200人(9.82%)接种新冠疫苗后就诊于全科医疗的1,482,273例不良事件。结果显示接种后就医不良事件总体略低于背景水平,Comirnaty和Vaxzevria接种后7天内发生率降低3-7%,Spikevax单剂后观察到20%增加。不同疫苗品牌间不良事件类型存在差异。
要点
- 接种新冠疫苗后就医不良事件总体略低于背景水平。
- Comirnaty和Vaxzevria接种后7天内不良事件发生率降低3-7%。
- Spikevax单剂后不良事件相对发生率增加20%。
核心结论
- 新冠疫苗与就医不良事件发生率的轻微降低相关。
- 哨点网络可常规报告常见不良事件率,有助于疫苗安全性报告。
研究设计与样本
- 采用自对照病例系列设计,数据来自英格兰国家哨点网络牛津-皇家学院全科医师临床信息数字中心。
- 研究期间为2020年10月1日至2021年9月12日,比较接种前7天与接种后7天不良事件与背景水平。
- 共纳入7,952,861条记录,其中781,200人(9.82%)因1,482,273例不良事件就诊于全科医疗,4.85%发生在接种后7天内。
主要发现
- 接种后就医不良事件总体较背景水平降低。
- Comirnaty首剂后7天内相对发生率RI为0.93(95%CI:0.91-0.94),第二剂后RI为0.96(95%CI:0.94-0.98)。
- Vaxzevria接种后7天内相对发生率RI为0.97(95%CI:0.95-0.98)。
- Spikevax单剂后相对发生率RI为1.20(95%CI:1.00-1.44)。
- 随年龄增长报告的不良事件减少;两剂Comirnaty后神经系统和精神科疾病增加(RI:1.41;95%CI:1.28-1.56),Vaxzevria后RI为1.07(95%CI:0.97-1.78)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundPost-authorisation vaccine safety surveillance is well established for reporting common adverse events of interest (AEIs) following influenza vaccines, but not for COVID-19 vaccines.AimTo estimate the incidence of AEIs presenting to primary care following COVID-19 vaccination in England, and report safety profile differences between vaccine brands.MethodsWe used a self-controlled case series design to estimate relative incidence (RI) of AEIs reported to the national sentinel network, the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub. We compared AEIs (overall and by clinical category) 7 days pre- and post-vaccination to background levels between 1 October 2020 and 12 September 2021.ResultsWithin 7,952,861 records, 781,200 individuals (9.82%) presented to general practice with 1,482,273 AEIs, 4.85% within 7 days post-vaccination. Overall, medically attended AEIs decreased post-vaccination against background levels. There was a 3-7% decrease in incidence within 7 days after both doses of Comirnaty (RI: 0.93; 95% CI: 0.91-0.94 and RI: 0.96; 95% CI: 0.94-0.98, respectively) and Vaxzevria (RI: 0.97; 95% CI: 0.95-0.98). A 20% increase was observed after one dose of Spikevax (RI: 1.20; 95% CI: 1.00-1.44). Fewer AEIs were reported as age increased. Types of AEIs, e.g. increased neurological and psychiatric conditions, varied between brands following two doses of Comirnaty (RI: 1.41; 95% CI: 1.28-1.56) and Vaxzevria (RI: 1.07; 95% CI: 0.97-1.78).ConclusionCOVID-19 vaccines are associated with a small decrease in medically attended AEI incidence. Sentinel networks could routinely report common AEI rates, contributing to reporting vaccine safety.
引用
- Tsang RS, Joy M, Byford R, et al. Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study. Euro Surveill. 2023. PMID: 36695484. doi:10.2807/1560-7917.ES.2023.28.3.2200195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。